NVCR Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

SPRZEDAż 108506 min ago

@ $15.54

Wydano: 14 vas. 2024 @ 19:55

Zwrot: -17.62%

Poprzedni sygnał: vas. 14 - 19:01

Poprzedni sygnał: Kupno

Zwrot: 1.34 %

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	957 402
Średni wolumen	1.29M
Kapitalizacja rynkowa	1.38B
EPS	$0 ( 2024-02-22 )
Następna data zysków	( $-0.420 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.56
ATR14	$0.0100 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Groenhuysen Wilhelmus Cm	Sell	2 107	Ordinary Shares
2024-03-04	Groenhuysen Wilhelmus Cm	Sell	1 217	Ordinary Shares
2024-03-01	Leonard Frank X	Sell	1 679	Ordinary Shares
2024-03-04	Leonard Frank X	Sell	840	Ordinary Shares
2024-02-27	Cordova Ashley	Buy	102 249	Ordinary Shares

INSIDER POWER
77.64
Last 92 transactions
Buy: 1 705 026 \| Sell: 238 995

Wolumen Korelacja

Długi: -0.29 (neutral)

Krótki: -0.74 (moderate negative)

Signal:(35.119) Neutral

Novocure Ltd Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Novocure Ltd Korelacja - Waluta/Towar

-0.36
( neutral )

-0.31
( neutral )

0.00
( neutral )

-0.02
( neutral )

0.58
( weak )

Novocure Ltd Finanse

Annual	2023
Przychody:	$509.34M
Zysk brutto:	$381.06M (74.81 %)
EPS:	$-1.950

FY	2023
Przychody:	$509.34M
Zysk brutto:	$381.06M (74.81 %)
EPS:	$-1.950

FY	2022
Przychody:	$537.84M
Zysk brutto:	$422.97M (78.64 %)
EPS:	$-0.880

FY	2021
Przychody:	$535.03M
Zysk brutto:	$420.15M (78.53 %)
EPS:	$-0.563

Financial Reports:

No articles found.

Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Aktualne aktualizacje dla Novocure Ltd [NVCR]

Upcoming Earnings Alert